3-O-methyl sorbitollysine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-O-methyl sorbitollysine
• 英文别名: 3-O-methylsorbitollysine；[(2S,3R,4R,5R)-2,4,5,6-tetrahydroxy-3-methoxyhexyl] (2S)-2,6-diaminohexanoate
• 化学式: C₁₃H₂₈N₂O₇
• 分子量: 324.375
• InChiKey: ZQXLGWFGMKJOIP-RNWYCLNJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.2
• 重原子数：
  22
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  169
• 氢给体数：
  6
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  α-carbobenzoxy-lysine 、 3-O-甲基-D-葡萄糖 在 5%-palladium/activated carbon sodium cyanoborohydride 、 氢气 作用下， 以 甲醇 、 水 、 正丁醇 为溶剂， 反应 432.0h， 以77%的产率得到3-O-methyl sorbitollysine
  参考文献：
  名称：

  Fructoseamine 3 kinase and the formation of collagen and elastin

  摘要：

  本发明涉及到一项发现，即通过改变Amadori途径的通量可以调节胶原蛋白和弹性蛋白的水平，并且含铜化合物和配合物可以抑制酶果糖胺-3-激酶。

  公开号：

  US20070065443A1

文献信息

• 3-deoxyglucosone and skin
  申请人：——

  公开号：US20030219440A1

  公开（公告）日：2003-11-27

  The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.

  该发明涉及一种从皮肤中去除3-去氧葡萄糖酮和其他α-二酮糖的方法。该发明还涉及抑制皮肤中3-去氧葡萄糖酮和其他α-二酮糖的产生和功能的方法。该发明还涉及治疗与皮肤相关的3-去氧葡萄糖酮和其他α-二酮糖相关疾病和障碍的方法。
• Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention
  申请人：——

  公开号：US20020111291A1

  公开（公告）日：2002-08-15

  Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins), which are believed to be a contributing cause of diabetic complications. Also disclosed are therapeutic methods of using such inhibitors to reduce formation of AGE-proteins and thereby lessen, reduce and delay diabetic complications and the effects of glycogen storage diseases, including Fanconi's syndrome. Methods for assessing a diabetic's risk of developing complications and for determining the efficacy of the disclosed inhibitor therapy by measuring the ratio of 3DG to 3DF in a biological sample following an oral dose of a fructose-lysine-containing food product are also disclosed.

  本文披露了一类化合物，可以抑制酶催化将果糖赖氨酸转化为果糖赖氨酸-3-磷酸酯的反应，这是一种新发现的代谢途径中依赖ATP的反应。根据该途径的正常功能，果糖赖氨酸-3-磷酸酯（FL3P）被分解为游离赖氨酸、无机磷酸盐和3-脱氧葡萄糖酮（3DG），后者是一种具有反应性的蛋白质修饰剂。3DG可以通过还原为3-脱氧果糖（3DF）来解毒，也可以与内源蛋白质反应形成高级糖基化终产物修饰的蛋白质（AGE-蛋白），据信这是糖尿病并发症的一个促发因素。此外，还披露了使用这种抑制剂的治疗方法，以减少AGE-蛋白的形成，从而减轻、减少和延迟糖尿病并发症和糖原贮积病（包括范科尼综合征）的影响。还披露了通过在口服含果糖赖氨酸的食品后测量生物样品中3DG与3DF比值来评估糖尿病患者发生并发症的风险和确定披露的抑制剂疗法的疗效的方法。
• EP1576093A4
  申请人：——

  公开号：EP1576093A4

  公开（公告）日：2009-07-08
• 3-DEOXYGLUCOSONE AND SKIN
  申请人：Dynamis Therapeutics, Inc.

  公开号：EP1576093A2

  公开（公告）日：2005-09-21
• FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN
  申请人：Dynamis Therapeutics, Inc.

  公开号：EP1753861A2

  公开（公告）日：2007-02-21